Cormorant Asset Management »

Cullinan Oncology shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Cullinan Oncology (CGEM) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Cullinan Oncology

Tip: Access up to 7 years of quarterly data

All positions including Cullinan Oncology held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cullinan Oncology by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $20M 1.1M 17.44
2021-03-31 $6.3M 150k 41.67

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Cullinan Oncology

MPM Oncology Impact Management
BVF
BlackRock
BlackRock
Deerfield Management Company
Vanguard Group
Paradigm Biocapital Advisors
Franklin Resources
Citadel Advisors
Blue Owl Capital Holdings
State Street Corporation
Alliancebernstein
Holocene Advisors
VR Adviser
Siren

View all funds holding Cullinan Oncology